[go: up one dir, main page]

PT1165558E - Derivados de pirimido¬6,1-a|isoquinolina-4-ona - Google Patents

Derivados de pirimido¬6,1-a|isoquinolina-4-ona

Info

Publication number
PT1165558E
PT1165558E PT00920857T PT00920857T PT1165558E PT 1165558 E PT1165558 E PT 1165558E PT 00920857 T PT00920857 T PT 00920857T PT 00920857 T PT00920857 T PT 00920857T PT 1165558 E PT1165558 E PT 1165558E
Authority
PT
Portugal
Prior art keywords
pyrimido
isokinolin
derivatives
ona
ona derivatives
Prior art date
Application number
PT00920857T
Other languages
English (en)
Inventor
Alexander William Oxford
David Jack
Original Assignee
Vernalis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9907454.4A external-priority patent/GB9907454D0/en
Priority claimed from GBGB9909802.2A external-priority patent/GB9909802D0/en
Application filed by Vernalis Ltd filed Critical Vernalis Ltd
Publication of PT1165558E publication Critical patent/PT1165558E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PT00920857T 1999-03-31 2000-03-29 Derivados de pirimido¬6,1-a|isoquinolina-4-ona PT1165558E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9907454.4A GB9907454D0 (en) 1999-03-31 1999-03-31 Compounds
GBGB9909802.2A GB9909802D0 (en) 1999-04-28 1999-04-28 Compounds

Publications (1)

Publication Number Publication Date
PT1165558E true PT1165558E (pt) 2004-02-27

Family

ID=26315369

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00920857T PT1165558E (pt) 1999-03-31 2000-03-29 Derivados de pirimido¬6,1-a|isoquinolina-4-ona

Country Status (16)

Country Link
US (5) US6794391B2 (pt)
EP (1) EP1165558B1 (pt)
JP (1) JP4685243B2 (pt)
CN (1) CN100415743C (pt)
AT (1) ATE250602T1 (pt)
AU (1) AU773504B2 (pt)
BR (1) BRPI0009446B8 (pt)
CA (1) CA2368413C (pt)
DE (1) DE60005493T2 (pt)
DK (1) DK1165558T3 (pt)
ES (1) ES2208310T3 (pt)
MX (1) MXPA01009846A (pt)
NO (1) NO20014728L (pt)
NZ (1) NZ514158A (pt)
PT (1) PT1165558E (pt)
WO (1) WO2000058308A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208310T3 (es) * 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
EP1898894A1 (en) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp iv inhibitors for the treatment of respiratory diseases
EP2138495A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
MY157432A (en) * 2010-08-09 2016-06-15 Verona Pharma Plc Crystalline form of pyrimido [6, 1-a] isoquinolin-4-one compound
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
MX2015011778A (es) * 2013-03-15 2015-12-01 Verona Pharma Plc Combinacion de farmaco.
ES2773142T3 (es) * 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
RS58897B1 (sr) * 2014-09-15 2019-08-30 Verona Pharma Plc Tečna inhalaciona formulacija koja sadrži rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) * 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
CA3106052A1 (en) 2018-07-13 2020-01-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tri-cyclic compound as pde3/pde4 dual inhibitor
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
CN114929701B (zh) * 2020-01-15 2024-11-05 正大天晴药业集团股份有限公司 一种pde3/pde4双重抑制剂的结晶及其应用
US20230060174A1 (en) * 2020-01-15 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
US20240217974A1 (en) * 2021-04-29 2024-07-04 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Isoquinolone compound and use thereof
EP4423085A1 (en) 2021-10-29 2024-09-04 Teva Pharmaceuticals International GmbH Solid state forms of ensifentrine and process for preparation thereof
AU2022414887A1 (en) * 2021-12-14 2024-07-25 Xizang Haisco Pharmaceutical Co., Ltd. Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof
WO2023138676A1 (zh) * 2022-01-21 2023-07-27 四川海思科制药有限公司 三环稠杂环类pde3/4双重抑制及其用途
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024033624A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd)
WO2024033627A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Liquid pharmaceutical composition
WO2024084212A1 (en) 2022-10-20 2024-04-25 Verona Pharma Plc Treatment of idiopatic pulmonary fibrosis with ensifentrine
WO2024088402A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的晶型及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2024127413A1 (en) * 2022-12-14 2024-06-20 Cipla Limited Solid state forms of ensifentrine
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025003643A1 (en) 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
CN118955496A (zh) * 2023-06-28 2024-11-15 郑州德迈药业有限公司 一种化合物及其应用
WO2025052119A1 (en) 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ185900A (en) * 1976-12-10 1981-04-24 Hoechst Ag Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4254118A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1-Oxo-5H-pyrimido[2,1-c][1,4]benzthiazine-2-carboxylic acid esters
US4307092A (en) * 1979-08-13 1981-12-22 Ayerst Mckenna & Harrison, Inc. 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters
US4254121A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 3-Oxo-5H-pyrimido[2,1-c][1,4 ]benzoxazines
CA1237429A (en) * 1983-05-05 1988-05-31 Frank Kienzle Pyrimidone derivatives
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE3816995A1 (de) * 1988-05-19 1989-11-23 Hoechst Ag Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10287655A (ja) * 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
ES2208310T3 (es) * 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.

Also Published As

Publication number Publication date
DK1165558T3 (da) 2004-02-09
ES2208310T3 (es) 2004-06-16
US20040176353A1 (en) 2004-09-09
ATE250602T1 (de) 2003-10-15
JP4685243B2 (ja) 2011-05-18
US8242127B2 (en) 2012-08-14
BR0009446A (pt) 2002-01-15
AU773504B2 (en) 2004-05-27
EP1165558A1 (en) 2002-01-02
BRPI0009446B8 (pt) 2021-05-25
DE60005493D1 (de) 2003-10-30
NO20014728D0 (no) 2001-09-28
NO20014728L (no) 2001-11-23
CN100415743C (zh) 2008-09-03
AU4127400A (en) 2000-10-16
US7105663B2 (en) 2006-09-12
NZ514158A (en) 2000-03-29
US20120302533A1 (en) 2012-11-29
US6794391B2 (en) 2004-09-21
EP1165558B1 (en) 2003-09-24
US20080206163A1 (en) 2008-08-28
JP2002540207A (ja) 2002-11-26
CN1348453A (zh) 2002-05-08
WO2000058308A1 (en) 2000-10-05
US7378424B2 (en) 2008-05-27
CA2368413A1 (en) 2000-10-05
BRPI0009446B1 (pt) 2016-11-01
MXPA01009846A (es) 2003-06-24
CA2368413C (en) 2008-07-29
US20040171828A1 (en) 2004-09-02
DE60005493T2 (de) 2004-07-01
US20030036542A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
PT1165558E (pt) Derivados de pirimido¬6,1-a|isoquinolina-4-ona
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
WO2001049688A8 (en) Purine derivatives, process for their preparation and use thereof
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
HUP0500163A3 (en) Pyrazolo [5,1-b]quinazoline derivatives and pharmaceutical compositions thereof as inhibitors of impdh enzyme
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
EP1443925B8 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
MY141978A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
DK0640086T3 (da) Mercaptoacetylamido-pyridazo[1,2-a][1,2]diazepin-derivateranvendelige som enkephalinase- og ACE-inhibitorer
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
CA2388476A1 (en) Bicyclic imidazo-5-yl-amine derivatives
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
AU2002366736A1 (en) Masked phosphate containing nucleoside derivatives and their use as antivirals
DE60008400D1 (de) Triazolopyrimidinderivate